Search - tctmd.com

Displaying 381 - 400 of 443

Sort: Relevancy | Date

News Conference News AHA 2016

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

Shelley Wood

November 09, 2016

News Opinion Editor's Corner TCT 2016

My Takeaways From TCT 2016: Surprises, Presuppositions, and the Gift of the Giveaway

Shelley Wood

November 07, 2016

News Industry News

Study Finds Use Of Adjuctive Cerebral Embolic Protection During Transcatheter Aortic Valve Replacement Was Safe But Improvement In MRI Findings Did Not Reach Statistical Significance

November 01, 2016

Presentation TCT 2016

Direct Annuloplasty II: Mitralign Trial Results and Future Directions

Presenter: Ted Feldman, Scott Lim, Azeem Latib

October 31, 2016

Presentation TCT 2016

Direct Annuloplasty I: Cardioband TF Trial Results and Future Directions

Presenter: Ted Feldman, Scott Lim, Francesco Maisano

October 31, 2016

Presentation TCT 2016

Rationale for and Design of COAPT: What I Expect the Findings to Be But What Wont Surprise Me!

Presenter: Michael Argenziano, Alec S. Vahanian, Blase A. Carabello

October 31, 2016

Presentation TCT 2016

Rationale for and Design of TAVR UNLOAD: What I Expect the Findings to Be But What Wont Surprise Me!

Presenter: Michael Argenziano, Alec S. Vahanian, Daniel Burkhoff

October 31, 2016

Presentation TCT 2016

Rationale for and Design of GALILEO

Presenter: Michael Argenziano, Alec S. Vahanian, Paul Sorajja

October 31, 2016

Presentation TCT 2016

Rationale for and Design of SAPIEN LOW RISK and EVOLUTE LOW RISK

Presenter: Michael Argenziano, Alec S. Vahanian, Patrick T. O'Gara

October 31, 2016

Presentation TCT 2016

Moderate Aortic Stenosis + Heart Failure: Introduction to the UNLOAD Trial

Presenter: A. Pieter Kappetein, Allan Schwartz, Martin B. Leon

October 30, 2016

Presentation TCT 2016

Low-Risk Studies: Design and Updates III - The Evolut R Low-Risk Trial

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Jeffrey J. Popma

October 30, 2016

Presentation TCT 2016

Low-Risk Studies: Design and Updates II - The PARTNER 3 Low-Risk Trial

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Michael J. Mack

October 30, 2016

Presentation TCT 2016

Intermediate-Risk Studies I: Synthesis of the PARTNER 2A and the Sapien 3 Intermediate-Risk Trials

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Susheel K. Kodali

October 30, 2016

News Opinion Editor's Corner TCT 2016

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

Shelley Wood

October 24, 2016

News Daily News

Amid Sparse Data on Infection After ASD Closure, Experts Urge Focus on Dental Health

Yael L. Maxwell

September 26, 2016

News Conference News PCR London Valves 2016

Leaflet Restriction After TAVR: Two Hospitals Tracking Patients Find Similar Rates of the Phenomenon

Shelley Wood

September 20, 2016

News Conference News PCR London Valves 2016

Innovation Overload? Too Many Novel Ideas May Be Holding Back Progress in Transcatheter Mitral Valve Technologies

Shelley Wood

September 19, 2016

News Daily News

Elderly Asymptomatic Patients With Severe AS Are Often Treated Too Late

L.A. McKeown

September 16, 2016

News Daily News

Stroke Risk With TAVR: In-Depth Review of PARTNER and CoreValve Data Reveals Opportunities and Unknowns

Shelley Wood

September 13, 2016

News Daily News

CLEAN-TAVI: Results of Cerebral Embolic Protection in TAVR Now in Print

Yael L. Maxwell

August 15, 2016

Advertisement

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

My Takeaways From TCT 2016: Surprises, Presuppositions, and the Gift of the Giveaway

Study Finds Use Of Adjuctive Cerebral Embolic Protection During Transcatheter Aortic Valve Replacement Was Safe But Improvement In MRI Findings Did Not Reach Statistical Significance

Direct Annuloplasty II: Mitralign Trial Results and Future Directions

Direct Annuloplasty I: Cardioband TF Trial Results and Future Directions

Rationale for and Design of COAPT: What I Expect the Findings to Be But What Wont Surprise Me!

Rationale for and Design of TAVR UNLOAD: What I Expect the Findings to Be But What Wont Surprise Me!

Rationale for and Design of GALILEO

Rationale for and Design of SAPIEN LOW RISK and EVOLUTE LOW RISK

Moderate Aortic Stenosis + Heart Failure: Introduction to the UNLOAD Trial

Low-Risk Studies: Design and Updates III - The Evolut R Low-Risk Trial

Low-Risk Studies: Design and Updates II - The PARTNER 3 Low-Risk Trial

Intermediate-Risk Studies I: Synthesis of the PARTNER 2A and the Sapien 3 Intermediate-Risk Trials

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

Amid Sparse Data on Infection After ASD Closure, Experts Urge Focus on Dental Health

Leaflet Restriction After TAVR: Two Hospitals Tracking Patients Find Similar Rates of the Phenomenon

Innovation Overload? Too Many Novel Ideas May Be Holding Back Progress in Transcatheter Mitral Valve Technologies

Elderly Asymptomatic Patients With Severe AS Are Often Treated Too Late

Stroke Risk With TAVR: In-Depth Review of PARTNER and CoreValve Data Reveals Opportunities and Unknowns

CLEAN-TAVI: Results of Cerebral Embolic Protection in TAVR Now in Print

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content